- Phosphodiesterase-4 Inhibitor increases lung, intracellular cAMP
- Bronchodilates and reduces inflammation
- Severe, refractory COPD with Chronic Bronchitis and frequent exacerbations
- Roflumilast Tablets: 250 mcg 500 mcg
- Roflumilast 500 mcg orally daily
- Gastrointestinal (common, intolerable in 5%)
- Other common symptoms
- Psychiatric (3%)
- Suicidality
- Depression
- Anxiety
- Unknown safety in pregnancy
- Unknown safety in Lactation
- Avoid in Lactation (is excreted in Breast Milk)
- Cytochrome P450 3A4 Inhibitors
- Cytochrome P450 3A4 and Cytochrome P450 1A2 Inducers
- NNT: 24 severe COPD patients to prevent 1 hospitalization per year
- Does not reduce mortality
- (2015) Presc Lett 22(5): 27
- Field (2011) Circ Respir Pulm Med 5: 57–70 [PubMed]